NCT06051409Phase 3Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Study sponsor: Ascentage Pharma Group Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12-31Estimated
Enrollment · participants350Estimated
Source updated2026-04-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Minimal residual disease negativity rate. After: Measure: Minimal Residual Disease Negative CR Rate.

Primary completion date changed

Before: 31 Dec 2024. After: 31 Dec 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview